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Dermic-derived fibroblasts for the 
study of amyotrophic lateral sclerosis
Among neurodegenerative diseases, amyotrophic lateral scle-
rosis (ALS) is the most frequent one involving motor neurons 
(MNs). ALS incidence varies throughout the world ranging 
from 0.7 to 4 cases per 100,000 habitants and year (Riancho et 
al., 2016). This disease, which currently lacks an effective ther-
apy, is characterized by a variable combination of upper and 
lower MN degeneration, leading to progressive muscle wasting 
which usually results in a terminal respiratory failure within 3 
years after symptom onset (Zufiria et al., 2016). A small propor-
tion of ALS cases show familial aggregation. These are related 
to mutations in specific causative genes (Cr9ORF72, TARDBP, 
FUS, SOD1 and others) which directly determine disease onset 
in carriers. By contrast, more than 90 percent of cases are con-
sidered to be sporadic, in which generally unknown environ-
mental and internal factors interact with genetic predisposing 
factors finally leading to disease (Riancho et al., 2018). From 
a histopathological point of view, ALS is characterized by MN 
damage and loss. MNs from ALS sporadic and most of familial 
patients exhibit prominent transactive response DNA-binding 
protein 43 (TDP-43) cytoplasmic aggregates which are con-
sidered as the “pathological hallmark” of the disease, except-
ing those related to SOD1 and FUS mutations (Zufiria et al., 
2016). TDP-43 is a DNA/RNA binding protein encoded by the 
TARDBP gene that controls the expression of many different 
genes.
Although during the last decade knowledge about ALS has 
notably expanded and many potential molecular mechanisms 
have been proposed, the pathogenesis of ALS has not been fully 
elucidated yet. In this vein, there are still crucial unsolved issues, 
such as, for example, what is the precise trigger of the disease 
and whether ALS is a multisystem disease or by contrary it only 
affects the central nervous system. As an unfortunate conse-
quence of the absence of definitive answers to those questions, 
we do not have an effective therapy to offer to ALS patients (Zu-
firia et al., 2016).
The deficient models of the disease: The lack of an effective 
treatment for ALS patients should prompt scientific community 
to be on the search for new therapies for the disease. Important-
ly, this is not a problem of not having worked on it, but a lack of 
success of the investigations carried out so far. Similarly to the 
situation of several neurodegenerative diseases, during the last 
decades, tens of drugs have been tried out in ALS patients with 
disappointing results. Somewhat surprisingly, many of them 
had highly promising results in animal models but then failed 
when tested in humans (Ittner et al., 2015). This should make us 
reflect on important issues, such as if we are using appropriate 
disease animal models, or whether experimental designs reflect 
an approach holistic enough to recapitulate the pathogenesis of 
the disease in humans (Ittner et al., 2015; Zufiria et al., 2016).  
The most commonly used ALS murine model, the SOD1 
mice, has been reported to be a suboptimal model due to the 
absence of TDP-43 cytoplasmic aggregates in spinal MNs or 
to a disproportionate degeneration of lower MNs in compar-
ison to upper MNs. In recent years, other animal and cellular 
models have been developed (Lutz, 2018). Among them, MN 
differentiation from induced pluripotential stem cells and the 
direct MN re-programming seem of particular interest (Pich-
er-Martel et al., 2016). However, these techniques are expensive, 
time consuming and also exhibit intrinsic technical difficulties 
mostly related to the intrinsic variability of reprogrammed cells 
(Picher-Martel et al., 2016). Within this scenario, the pursuit 
of simpler and patient-derived models that might be used as 
an individualized biological avatar for both the investigation 
of pathogenic features and initial drug screening targeted to an 
individual case appear particularly interesting.
Fibroblasts as a potential easy-manageable ALS model in a 
“multi-systemic disease”: The absence of feasible and clinical-
ly-relevant models to explore disease biomarkers and potential 
therapies, motivated us to evaluate dermis-derived fibroblasts as 
a potential simple, viable, rapid and cost-efficient cellular model 
of ALS. Previously, other authors worked with skin fibroblasts of 
ALS patients, specifically with patients with familial ALS, with 
partially discordant or uncertain results (Sabatelli et al., 2015) 
(Figure 1). In our study, primary fibroblasts were obtained from a 
4-mm diameter human punch skin biopsy and cultured with Dul-
becco’s modified eagle medium/20% fetal bovine serum as previ-
ously published. Following this simple protocol, cells were avail-
able for experiments within a few weeks. In this manner, we were 
able to corroborate previous results that pointed out that skin-de-
rived fibroblasts from ALS patients show a reduced proliferation 
rate (Riancho et al., 2020). Very interestingly, we documented that 
ALS fibroblasts exhibited some degree of TDP-43 proteinopathy. 
Specifically, we observed that ALS fibroblasts had a partial loss of 
nuclear TDP-43, as well as an increased tendency for cytoplasmic 
TDP43 aggregation (Riancho et al., 2020). We consider these re-
sults of particular interest since they might be recapitulating the 
“key ALS pathogenetic hallmark” in MNs, with a double mecha-
nism of both TDP-43 loss of function - gain of function. In other 
words, the abnormalities seen in these accessible cells may be the 
same as those taking place in the inaccessible MNs. Of note, one 
group previously reported that primary fibroblasts did not recapit-
ulate such alterations (Codron et al., 2018). In our opinion, these 
discordances may be due to several culture-related factors, such 
as cell confluence degree or growing medium conditions, which 
might induce cellular stress and consequently make cells more 
vulnerable to TDP-43 misslocalization. 
Besides the TDP-43 proteinopathy, we demonstrated that der-
mic ALS derived fibroblasts exhibited deficient DNA damage 
reparation mechanisms (Riancho et al., 2020). Defective DNA 
damage response has been suggested to be an important patho-
genic mechanism in several  neurodegenerative diseases. Along 
this concept, neurons, as post-mitotic cells, would progressively 
accumulate DNA damage until they reach a threshold, from 
Figure 1 A representative confocal image of double fluorescent 
labelling for TDP-43 (green) and propidium iodide (red) in an 
ALS-derived fibroblast. 
Note several cytoplasmic aggregates of TDP-43, as well as a partial loss 
of TDP43 nucleoplasmic signal. Scale bar: 10 μm. ALS: Amyotrophic 
lateral sclerosis; TDP-43: transactive response DNA-binding protein 43.
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which the neuron would not be able to function normally and 
eventually would degenerate. In this framework, subjects with 
neurodegenerative diseases, including ALS, would exhibit high-
er susceptibility to accumulate DNA damage foci (Madabhushi 
et al., 2014). 
Regarding ALS, several genetic forms of the disease, includ-
ing Cr9ORF72 or FUS, had been associated with defective DNA 
damage response. Nevertheless, it had not been previously com-
municated in sporadic cases. Hence, our results provide new ev-
idences supporting the role of DNA damage response pathways 
in the pathogenesis of ALS (Riancho et al., 2020). Intriguingly, 
abnormal responses seem to be extensive to non-neuronal cel-
lular populations.
In addition to fibroblasts, although less studied, other periph-
eral and accessible cell populations such as peripheral blood 
mononuclear cells have also been assessed in ALS patients. In 
their studies, De Marco et al. (2017) reported a pathological 
TDP-43 accumulation in circulating lymphomocytes of both 
ALS patients with familial TDP-43 mutations and sporadic ALS 
cases. Regarding mature blood circulating monocytes, the same 
pathological TDP-43 deposit was described in several sub-
groups of ALS patients.
We believe that these results encompass important conse-
quences from a double point of view. Firstly, and in addition to 
murine and more sophisticated/complex models of the disease, 
simple and easily obtainable cellular models as dermic primary 
fibroblasts emerge as a useful tool to study TDP-43 proteinopa-
thy, an ALS hallmark,  which might be valuable for investigating 
pathogenic hypothesis as well as for the screening of new drugs 
in a cellular model directly relevant to human disease. 
Secondly, the involvement of non-neuronal populations 
support the conception that ALS might not only be a central 
nervous system disorder but also a systemic disease affecting 
peripheral neural and non-neural tissues (Zufiria et al., 2016). 
In line with this conception, several investigations have demon-
strated the involvement of non-neural structures in ALS. In 
addition to the recently described TDP-43 deposition in cuta-
neous, somatic and autonomic nerves of ALS patients, a patho-
logical increased TDP-43 expression was stated in the skin of 
patients with ALS (Suzuki et al., 2010). As a further support of 
the value of these observations, there is a correlation between 
protein expression and the duration of the disease (Suzuki et al., 
2010). 
Moreover, it has been hypothesized that ALS progression 
might be enforced by subjacent metabolic abnormalities, includ-
ing both fatty acid and carbohydrate metabolism (Zufiria et al., 
2016). This concept lies on diverse clinical and analytical studies 
documenting an unexpected increased ALS incidence among 
subjects with low body mass index, professional sportsmen, and 
subjects undergoing very restrictive diets (Riancho et al., 2018). 
Furthermore, certain metabolic abnormalities, mainly related to 
the lipid profile, have also been reported in ALS patients.
Concluding remarks: There is an urgent need to make new 
therapies available for ALS patients. ALS seems to be not cir-
cumscribed to the central nervous system. Instead, it may be 
more widespread, a systemic disorder involving non-neuronal 
cellular populations. Upon this concept, dermic fibroblasts 
emerge as a new, rapid, economic and manageable cellular 
model that recapitulates, at least partially, the pathogenesis of 
the disease seeming to be a promising tool for both pathogenic 
studies, identification of new therapeutic targets and early drug 
screening.
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